GSK plc (LON:GSK) Insider Julie Brown Acquires 10 Shares

GSK plc (LON:GSK) insider Julie Brown bought 10 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of GBX 1,351 ($17.98) per share, for a total transaction of £135.10 ($179.80).

GSK Trading Down 3.0%

GSK opened at GBX 1,358 ($18.07) on Wednesday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market cap of £55.11 billion, a price-to-earnings ratio of 21.94, a P/E/G ratio of 1.24 and a beta of 0.31. The stock’s 50 day moving average price is GBX 1,420.46 and its 200-day moving average price is GBX 1,396.66. GSK plc has a one year low of GBX 1,242.50 ($16.54) and a one year high of GBX 1,823.50 ($24.27).

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities analysts forecast that GSK plc will post 175.980975 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, April 30th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Friday, March 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of GBX 1,862.50 ($24.79).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.